Skip to main content
  1. Home
  2. Promotions
  3. GenetiSure Dx Postnatal Assay Technical Information

GenetiSure Dx Postnatal Assay Technical Information

GenetiSure DX banner

Designed for what matters
  • Genetisure Dx Postnatal Array is designed to allow the identification of copy number and copy neutral changes across the entire genome.
  • Each microarray contains approximately 107,000 probes optimized for copy number (CN) analysis, and 59,000 bi-allelic SNP probes.
  • The CN probes are distributed across the entire genome with a higher density in regions designated to be of clinical interest.
  • Oligonucleotide quality allows CN calls with as low as 5 consecutive probes

Assay resolution, not only numbers

  • The probes are distributed on the array, targeting overall 94% of the genome with at least 5 CN probes per 400 kb, resulting in a median resolution of approx. 150Kb.
  • Regions identified to be clinically relevant are targeted with increased probe density resulting in a median resolution of approximately 25Kb.
  • The SNP probes, for LOH and UPD detection, target 91% of the genome with at least 100 or more SNP probes for 10 Mb, resulting in a median resolution for LOH of approx. 8Mb.
  • Assay is able to detect mosaic amplifications and deletions spanning 100 or more probes

Built-in Quality Controls

The Genetisure Postnatal Dx Assay includes a series of in-process QC checks that allow the user to easily monitor and assess the quality of results. The controls include:

  • Validated reference DNA
  • Array QC metrics
  • Workflow QC checkpoint

Assay workflow validated for the laboratory

The Assay is comprehensive and easy to implement in the laboratory routine.

  • Only 500ng of genomic DNA are required for testing, extracted from 200µl of whole blood
  • The accuracy of GenetiSure Dx Postnatal Assay results is not affected by increased levels of hemoglobin, conjugated bilirubin, unconjugated bilirubin and triglycerides in the patient’s whole blood in EDTA or by conservation of blood up to 7 days.
  • The workflow is fully optimized and easy to set up. Segregation of lab space is not required as there is no PCR amplification steps.
  • The whole protocol, including interpretation, can be run in 3 days.

For more information, please visit www.agilent.com/chem/contactus.

INTENDED USE: GenetiSure Dx Postnatal Assay is a qualitative assay intended for the postnatal detection of copy-number variations (CNV) and copy-neutral loss of heterozygosity (cnLOH) in genomic DNA obtained from peripheral whole blood in patients referred for chromosomal testing based on clinical presentation. GenetiSure Dx Postnatal Assay is intended for the detection of CNVs and cnLOH associated with developmental delay, intellectual disability, congenital anomalies or dysmorphic features. Assay results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmation by alternative methods, parental evaluation, clinical genetic evaluation and counseling, as appropriate. Interpretation of assay results is intended to be performed only by healthcare professionals who are board-certified in clinical cytogenetics or molecular genetics.

The assay is intended to be used on the SureScan Dx Microarray Scanner System and analyzed by CytoDx Software.

WARNING: This device is not intended to be used for standalone or diagnostic purposes, pre-implantation or prenatal testing or screening, population screening or the detection of, or screening for, acquired or somatic genetic aberrations.

The products referenced on this page are not available for sale in all countries or jurisdictions. The information contained in this website may not be valid in your jurisdictions. Please contact your local sales representative for additional information.